Shanghai Haohai Biological Technology Co., Ltd.
688366
Rank in Stocks
#9050
Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise... Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise specializing in the research, development, manufacturing, and distribution of advanced biomedical materials. Its operations span Mainland China, the United States, the United Kingdom, and various international markets. The company's extensive product portfolio serves multiple medical fields. For ophthalmology, offerings include intraocular lenses, ophthalmic viscoelastic devices, specialized orthokeratology and phakic refractive lenses, eye drops, injectors, and surgical scalpels. In orthopedics, they provide sodium hyaluronate injections and medical chitosan. Their wound care segment features recombinant human epidermal growth factor, effective in treating a broad spectrum of injuries, including burns, residual wounds, donor site trauma, post-traumatic wounds, and both acute and chronic ulcerations. Anti-adhesion solutions are offered in the form of medical sodium hyaluronate gel and medical chitosan, while hemostatic products include collagen sponges and porcine fibrin sealants. Within medical aesthetics, Shanghai Haohai produces a diverse range of hyaluronic acid (HA) dermal fillers: Matrifill, a first-generation mono-phase injectable gel; Janlane, a second-generation filler engineered for dynamic applications; and Hyalumatrix, a third-generation product designed for precise aesthetic enhancements. This division also supplies radio frequency devices and laser equipment. Beyond its core product offerings, the company actively pursues research and development in biological engineering and pharmaceutical innovations. It also provides related technology transfer and consultation services, alongside engaging in investment and trading activities. Originally established in 2007 as Haohai Limited, the company adopted its current name, Shanghai Haohai Biological Technology Co., Ltd., in 2010 and is headquartered in Shanghai, China.
Share Price
$4.40
Last synced: 2026-11-10
Market Cap
$921.42M
Change (1 day)
-0.48%
Change (1 year)
-39.82%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Shanghai Haohai Biological Technology Co., Ltd. (688366)
Category
Healthcare
EPS for Shanghai Haohai Biological Technology Co., Ltd. (688366)
EPS as of September 2026 TTM: $0.07
According to Shanghai Haohai Biological Technology Co., Ltd.'s latest financial reports, its current EPS (TTM) is $0.07. At the end of 2025 the company had an EPS of $0.15, a decrease compared to its 2024 EPS of $0.25.
EPS history for Shanghai Haohai Biological Technology Co., Ltd. from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.07 | -51.00% |
| 2025 | $0.15 | -37.39% |
| 2024 | $0.25 | -0.24% |
| 2023 | $0.25 | 221.88% |
| 2022 | $0.08 | -52.15% |
| 2021 | $0.16 | 58.91% |
| 2020 | $0.10 | -39.38% |
| 2019 | $0.17 | -13.18% |
| 2018 | $0.19 | 4.92% |
| 2017 | $0.18 | 30.92% |
| 2016 | $0.14 | -4.51% |
| 2015 | $0.15 | 16.20% |
| 2014 | $0.13 | 27.30% |
| 2013 | $0.10 | -35.06% |
| 2012 | $0.15 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 21,206.12% |
US
|
|
| $-7.07 | -9,719.05% |
US
|
|
| $-5.29 | -7,297.28% |
AU
|
|
| $12.88 | 17,423.95% |
BE
|
|
| $21.56 | 29,233.33% |
NL
|
Questions about Shanghai Haohai Biological Technology Co., Ltd.'s earnings per share (EPS)
What is Shanghai Haohai Biological Technology Co., Ltd.'s earnings per share (EPS)?
Shanghai Haohai Biological Technology Co., Ltd.'s earnings per share (EPS) over the last twelve months is $0.07, as of Sep 2026.
What was Shanghai Haohai Biological Technology Co., Ltd.'s earnings per share (EPS) in 2025?
In 2025, Shanghai Haohai Biological Technology Co., Ltd.'s earnings per share (EPS) was $0.15, 40.00% less than in 2024 ($0.25).
How has Shanghai Haohai Biological Technology Co., Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Shanghai Haohai Biological Technology Co., Ltd.'s earnings per share (EPS) went from $0.10 to $0.15, an average growth of 8.45% a year.
How does Shanghai Haohai Biological Technology Co., Ltd.'s earnings per share (EPS) compare with similar companies?
Shanghai Haohai Biological Technology Co., Ltd.'s earnings per share (EPS) ($0.07) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.